TransMedics Group (NASDAQ:TMDX) Shares Up 4.2% – Still a Buy?

09 Oct 2026, 13:03 by Doug Wharley · The Cerbat Gem

TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) shot up 4.2% during trading on Wednesday. The company traded as high as $83.76 and last traded at $83.6560. Approximately 387,111 shares were traded during trading, a decline of 62% from the average session volume of 1,006,125 shares. The stock had previously closed at $80.28.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on TMDX shares. TD Cowen reiterated a “buy” rating and issued a $120.00 target price on shares of TransMedics Group in a research report on Tuesday, September 8th. Zacks Research cut TransMedics Group from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Canaccord Genuity Group reissued a “buy” rating and set a $124.00 price objective on shares of TransMedics Group in a research note on Tuesday, June 30th. Barclays initiated coverage on shares of TransMedics Group in a report on Wednesday. They issued an “overweight” rating and a $120.00 price objective for the company. Finally, Stifel Nicolaus increased their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research note on Thursday, June 18th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $121.00.

Get Our Latest Stock Report on TransMedics Group

TransMedics Group Stock Performance

The company has a market cap of $2.69 billion, a price-to-earnings ratio of 20.00, a price-to-earnings-growth ratio of 1.11 and a beta of 1.94. The firm has a 50-day simple moving average of $85.98 and a 200 day simple moving average of $83.97. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62.

TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.06). The business had revenue of $189.95 million during the quarter, compared to analysts’ expectations of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. TransMedics Group’s quarterly revenue was up 20.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.92 earnings per share. On average, sell-side analysts predict that TransMedics Group, Inc. will post 1.46 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In related news, Director David Weill bought 1,336 shares of the company’s stock in a transaction on Friday, September 11th. The stock was bought at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the acquisition, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. This represents a 8.87% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TMDX. GAMMA Investing LLC increased its position in TransMedics Group by 17.3% during the third quarter. GAMMA Investing LLC now owns 1,978 shares of the company’s stock worth $165,000 after buying an additional 292 shares in the last quarter. Farther Finance Advisors LLC boosted its holdings in TransMedics Group by 162.6% in the third quarter. Farther Finance Advisors LLC now owns 2,594 shares of the company’s stock valued at $216,000 after acquiring an additional 1,606 shares during the last quarter. Plan A Wealth LLC raised its holdings in shares of TransMedics Group by 3.9% in the 3rd quarter. Plan A Wealth LLC now owns 5,370 shares of the company’s stock worth $448,000 after purchasing an additional 203 shares during the period. Congress Asset Management Co. increased its position in TransMedics Group by 11.0% during the 3rd quarter. Congress Asset Management Co. now owns 252,952 shares of the company’s stock worth $21,109,000 after purchasing an additional 25,118 shares in the last quarter. Finally, Central Pacific Bank Trust Division acquired a new position in shares of TransMedics Group during the 3rd quarter valued at $702,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

(Get Free Report)

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.